GlaxoSmithKline plc is expected to file for approval of Relovair in both the U.S. and Europe in the middle of this year for chronic obstructive pulmonary disease (COPD), following the completion of the Phase III program. Commercialization of the potentially multi-billion-dollar product could be a boon for long-time partner Theravance Inc.